ECSP17036251A - Compuestos para tratar el cáncer - Google Patents

Compuestos para tratar el cáncer

Info

Publication number
ECSP17036251A
ECSP17036251A ECIEPI201736251A ECPI201736251A ECSP17036251A EC SP17036251 A ECSP17036251 A EC SP17036251A EC IEPI201736251 A ECIEPI201736251 A EC IEPI201736251A EC PI201736251 A ECPI201736251 A EC PI201736251A EC SP17036251 A ECSP17036251 A EC SP17036251A
Authority
EC
Ecuador
Prior art keywords
compounds
treat cancer
mps
prodrugs
prophylaxis
Prior art date
Application number
ECIEPI201736251A
Other languages
English (en)
Inventor
Gerhard Siemeister
Ulrich Lücking
Ursula Krenz
Antje Margret Wengner
Volker Schulze
Hans-Georg Lerchen
Philip Lienau
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ECSP17036251A publication Critical patent/ECSP17036251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Derivados de profármacos de inhibidores de la quinasa Mps-1 y su uso en el tratamiento y/o la profilaxis de enfermedades.
ECIEPI201736251A 2014-12-09 2017-06-09 Compuestos para tratar el cáncer ECSP17036251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196859 2014-12-09

Publications (1)

Publication Number Publication Date
ECSP17036251A true ECSP17036251A (es) 2017-06-30

Family

ID=52011093

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201736251A ECSP17036251A (es) 2014-12-09 2017-06-09 Compuestos para tratar el cáncer

Country Status (27)

Country Link
US (1) US20170342064A1 (es)
EP (1) EP3230285A1 (es)
JP (1) JP2017537116A (es)
KR (1) KR20170088872A (es)
CN (1) CN107001376A (es)
AR (1) AR102947A1 (es)
AU (1) AU2015359593A1 (es)
BR (1) BR112017012317A2 (es)
CA (1) CA2969902A1 (es)
CO (1) CO2017005741A2 (es)
CR (1) CR20170243A (es)
CU (1) CU20170078A7 (es)
DO (1) DOP2017000136A (es)
EA (1) EA201791264A1 (es)
EC (1) ECSP17036251A (es)
IL (1) IL252237A0 (es)
MA (1) MA41136A (es)
MX (1) MX2017007655A (es)
NI (1) NI201700072A (es)
PE (1) PE20170927A1 (es)
PH (1) PH12017501063A1 (es)
SG (1) SG11201704684PA (es)
TN (1) TN2017000241A1 (es)
TW (1) TW201625565A (es)
UY (1) UY36421A (es)
WO (1) WO2016091825A1 (es)
ZA (1) ZA201704589B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917467A (zh) * 2021-01-22 2023-10-20 渤健马萨诸塞州股份有限公司 用以增加重组病毒载体滴度的微管去稳定剂添加剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas

Also Published As

Publication number Publication date
TW201625565A (zh) 2016-07-16
ZA201704589B (en) 2019-02-27
PE20170927A1 (es) 2017-07-13
BR112017012317A2 (pt) 2018-04-24
NI201700072A (es) 2017-07-17
DOP2017000136A (es) 2017-08-31
MX2017007655A (es) 2017-10-11
JP2017537116A (ja) 2017-12-14
CO2017005741A2 (es) 2017-08-31
US20170342064A1 (en) 2017-11-30
PH12017501063A1 (en) 2017-12-11
IL252237A0 (en) 2017-07-31
AU2015359593A1 (en) 2017-06-08
CA2969902A1 (en) 2016-06-16
CN107001376A (zh) 2017-08-01
EA201791264A1 (ru) 2017-12-29
CR20170243A (es) 2017-07-26
MA41136A (fr) 2017-10-17
EP3230285A1 (en) 2017-10-18
UY36421A (es) 2016-06-30
SG11201704684PA (en) 2017-07-28
WO2016091825A1 (en) 2016-06-16
AR102947A1 (es) 2017-04-05
KR20170088872A (ko) 2017-08-02
TN2017000241A1 (en) 2018-10-19
CU20170078A7 (es) 2017-10-05

Similar Documents

Publication Publication Date Title
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
PT3377516T (pt) Composição para o tratamento do cancro
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PT3119762T (pt) Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
HRP20180697T1 (hr) Spojevi imidazo[4,5-c]kinolin-2-ona i njihova upotreba za liječenje raka
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
LT3601296T (lt) 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer